Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
EARLY_PHASE1
5 participants
INTERVENTIONAL
2014-05-02
2014-09-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of ∆-9-THC and Naloxone in Humans
NCT01591629
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
NCT03221231
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
NCT02709954
PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults
NCT05906511
Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC
NCT05287256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active N-acetylcysteine and Active Delta-9-THC
Delta-9-THC
Active Delta-9-THC (0.036mg/Kg) given intravenously.
N-acetylcysteine
A pill given orally.
Placebo and Active Delta-9-THC
Delta-9-THC
Active Delta-9-THC (0.036mg/Kg) given intravenously.
Placebo
Placebo "sugar" pill given orally with no N-acetylcysteine.
Active N-acetylcysteine and Placebo
N-acetylcysteine
A pill given orally.
Placebo
Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
Placebo and Placebo
Placebo
Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
Placebo
Placebo "sugar" pill given orally with no N-acetylcysteine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Delta-9-THC
Active Delta-9-THC (0.036mg/Kg) given intravenously.
N-acetylcysteine
A pill given orally.
Placebo
Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
Placebo
Placebo "sugar" pill given orally with no N-acetylcysteine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Individuals with a documented allergy to N-acetylcysteine
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohini Ranganathan
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohini Ranganathan, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Connecticut Healthcare System
West Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1402013406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.